Sarepta Therapeutics, Inc.

Sarepta Therapeutics announced its second quarter 2026 financial results, reporting total revenues of $401.3 million, a 34% decrease year-over-year, and a GAAP net loss of $(4.9) million. The company also announced the appointment of Michael Severino, MD, as its new Chief Executive Officer. Sarepta narrowed its full-year 2026 total net product revenue guidance to $1.2-$1.3 billion and reported a strong cash position of $945.0 million. Key pipeline and regulatory updates include progress in DM1, FSHD, and Huntington's disease programs, and FDA acceptance of sNDAs for AMONDYS 45 and VYONDYS 53.

Sarepta Therapeutics reported a net income of $326.07 million for the six months ended June 30, 2026, a significant improvement from a net loss of $(250.62) million in the prior year period. However, the second quarter of 2026 saw a net loss of $(4.89) million, compared to a net income of $196.89 million in Q2 2025. Total revenues for the six months decreased to $1.13 billion, while Q2 revenues were $401.25 million. The company recognized $365 million in collaboration revenue from Roche, including $325 million from a declined option, and continues to address regulatory pathways for ELEVIDYS.

Sarepta Therapeutics' stockholders approved the 2026 Equity Incentive Plan, authorizing 6,286,841 shares, and the 2026 Employee Stock Purchase Plan, authorizing 1,500,000 shares, at its Annual Meeting. Additionally, five Class I directors were elected, named executive officer compensation for 2025 received advisory approval, and KPMG LLP was ratified as the independent auditor for 2026.

Sarepta Therapeutics reported Q1 2026 GAAP net income of $331.0 million and GAAP operating income of $358.4 million, marking a significant turnaround from losses in Q1 2025. Total revenues were $730.8 million, a slight decrease year-over-year, primarily due to lower ELEVIDYS sales from an updated label. The company also announced positive early clinical data from its siRNA pipeline for FSHD1 and DM1, advanced enrollment in ENDEAVOR Cohort 8 for ELEVIDYS, and submitted sNDAs for traditional approval of AMONDYS 45 and VYONDYS 53. Sarepta reiterated its full-year 2026 guidance for total net product revenues of $1.2 - $1.4 billion.

Sarepta Therapeutics reported a significant financial turnaround in Q1 2026, achieving a net income of $330.96 million, a substantial improvement from a net loss of $447.51 million in Q1 2025. This positive shift was primarily driven by a $325 million collaboration revenue recognition from Roche declining an option and a $40 million milestone payment, alongside a sharp reduction in research and development expenses. However, total product revenues, particularly ELEVIDYS sales, experienced a notable decline. The company continues to navigate regulatory challenges for ELEVIDYS, especially concerning non-ambulatory patients.

Sarepta Therapeutics, Inc. announced its Annual Meeting of Stockholders will be held virtually on June 4, 2026. Key agenda items include the election of five Class I directors, an advisory vote on named executive officer compensation, and the approval of both the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan. Stockholders will also vote to ratify KPMG LLP as the independent registered public accounting firm for the current year. The Board of Directors recommends a vote FOR all proposals.

Sarepta Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) for its Annual Meeting of Stockholders to be held virtually on June 4, 2026. Stockholders will vote on the election of five Class I directors, an advisory resolution on named executive officer compensation, and the approval of the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan. Additionally, the ratification of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2026, is on the agenda. The Board of Directors recommends a vote FOR all proposals.